ABSTRACT
The presence of obsessive compulsive (OC) symptoms in schizophrenic patients have been reported for decades. Recent studies have reported that OC symptoms occur in large number of schizophrenic patients varying from 13-25% (Bermanetal.,1995; Cossofetal., 1998; Fenton & Mcglashan,1986) . Presence of persistent OC symptoms represents an indicator of poor prognosis (Fenton & Mcglashan, 1986; Samuel et al.,1993) . These patients have been reported to be more socially isolated, less likely to work and need longer hospitalization than non OC schizophrenic patients (Fenton & Mcglashan, 1986; Samuel et al.,1993) . Fluoxetine has been reported to improve negative symptoms when added to neuroleptics in schizophrenic patients (Goff et al.,1995) . However, later studies have failed to find any improvement in positive or negative symptoms when fluoxetine was added to Clozapine and conventional antipsychotics (Arango et al.,2000) . There are several case reports that described patients who showed improvement in OC symptoms when fluoxetine was added to their ongoing neuroleptic medication (Sewell et al.,1994 , Tejera et al.,1994 . However there is no study in literature that confirms the efficacy of fluoxetine in OC symptoms in schizophrenic patients. We report an open pilot study in which fluoxetine was added to the ongoing neuroleptic medication of schizophrenic patients with OC symptoms.
MATERIAL AND METHOD
Seven outpatients (6 male, 1 female) with mean±SD age 25.7±6.6 years (range 18-35 years) were included in the study. The diagnosis of schizophrenia was confirmed by information from relatives of the patients, chart review and clinical interview of the patients using DSM-IV criteria. OC symptoms were diagnosed by Fenton and McGlashan (1986) criteria. Patients with comorbid axis I disorders and clinically significant physical illness were excluded. Patients were stable on same dosage of their neuroleptic medication at least for one month prior to inclusion in the study. All the patients or their relatives (whichever applicable) gave written informed consent for participation in the study after being provided details of procedure. Detailed history was taken and physical examination was carried out. Routine blood investigations were carried out. Patients were assessed on Positive and Negative Syndrome Scale (PANSS; Kay et al., 1987) , Yale Brown Obsessive Compulsive Scale (YBOCS; Goodman et al., 1989) , Clinical Global Impression scale (CGI; NIMH 1985) and Dosage Record Treatment Emergent Symptom Scale (DOTES; Campbell and Palij 1985) at baseline and thereafter at every two weeks throughout the study period of 12 weeks. All the scales were administered to the patients by one clinician (first author) throughout the study. 20 mg fluoxetine was added to their neuroleptic medication in first two weeks then increased to 40 mg from 3rd week, thereafter doses of fluoxetine were increased on the basis of clinical judgement to 60 mg from 5th week and 80 mg from 9th week. Compliance was ensured through counselling of the patient and family members taking care of the patient. Drugs were administered to the patient daily under direct supervision of close family member taking care of the patient. Baseline scores of PANSS, YBOCS and CGI were compared with the final scores at 12th week using paired t' test (two tailed).
RESULTS
All the patients completed the study period of 12 weeks. Mean duration of illness was 7.35±4.9 years. Mean dose of fluoxetine was 74 mg/day (range 40-80 mg). The antipsychotics given to the patients were haloperidol (n=1), trifluoperazine (n=1), injection fluphenazine (n=1), risperidone (n=3) and clozapine (n=1). Concomittant medication given were antiparkinsonian (n=3) and benzodiazepine (n=1). Five patients showed response in both OC and schizophrenic symptoms while 2 did not show any response.
Ratings on YBOCS (Table) at 12 weeks showed a significant improvement (p <01) as compared to baseline. Total scores on PANSS also showed a significant improvement (p<.004). Further analysis of PANSS subscales showed significant improvement in positive symptoms (p<.01), negative symptoms (p<.006) and general psychopathology (p<.004) as compared to baseline. Score of severity of illness on CGI showed a significant reduction (p<.01). Ratings of patients on CGI global improvement of individual patient showed very much improvement in 1, much improvement in 3, minimal improvement in 1 and no change in 2 patients. All patients tolerated fluoxetine well. Two patients developed restlessness and palpitation in first week which subsided in one week. Two patients complained of mild anorexia while one developed moderate anorexia which gradually decreased after four weeks. Two patients developed mild tremors and occasional headache tolerance to which developed in four weeks. None of the patient developed worsening of psychotic symptoms.
DISCUSSION
Evidence from this preliminary open trial suggest that fluoxetine was effective in reducing OC symptoms in schizophrenic patients. An OBSESSIVE COMPULSIVE SYMPTOMS IN SCHIZOPHRENIA improvement in residual schizophrenic symptoms was also observed. It also improved the global picture of the schizophrenic patients. The findings are interesting with the current evidence of dysfunction of serotonin in schizophrenia (Roth & Meltzer,1995) and obsessive compulsive disorder (Pigott,1996) . Also OC symptoms respond to serotonergic drugs like fluoxetine (Montgomery et al.,1993 , Tollofson et al.,1994 and clomipramine (Clomipramine Collaborative Study Group 1991) . Findings of our study suggest that OC symptoms in schizophrenic patients respond to fluoxetine in much the same way as OC symptoms in non schizophrenic patients. The improvement in residual schizophrenic symptoms is less clear. One possible explanation for improvement in schizophrenic symptoms could be the increase in the blood levels of neuroleptics because fluoxetine may increase the blood levels by inhibition of cytochrome p450 2d6 enzyme (Arango et al.,2000; Jefferson, 1998) . As other than two non-responders none of the patient was treatment resistant so higher dose of neuroleptics may cause an improvement in schizophrenic symptoms. Improvement in general symptoms could be explained by reduction in depression and anxiety associated with obsession. Another possible mechanism of improvement in schizophrenic symptoms could be the effect of serotonin on dopaminergic system as there is evidence that serotonin may modulate dopaminergic system physiologically at various levels in brain (Roth & Meltzer,1995) . Whatever the mechanism the fluoxetine was effective and well tolerated by the patients.
Both the non-responders were male and treatment resistant patients. One showed response to clozapine and was maintained on • clozapine 500 mg while other had history of nonresponse to clozapine. Their OC symptoms were present prior to the administration of clozapine. The mechanism of non response in one patient could be the antagonistic effects of fluoxetine and clozapine on the serotonin system. It is also possible that they may respond to a different antiobsessional agent as both of them were given fluoxetine as a first antiobsessional agent. The major limitations of the study were open trial, absence of the comparison group and small sample size. The preliminary findings suggest that fluoxetine was safe and effective in treatment of OC symptoms in schizophrenia. However mere is the need of controlled trials on larger sample to confirm the findings of this study.
